Lyra Medical was established in 2011 by a team of seasoned medical device entrepreneurs to develop a new, safer way to implant an organ support mechanism in women suffering from pelvic organ prolapse (POP).

The company’s Self-Retaining Support (SRS) technology is presently being applied in the flagship Lyra system for anterior vaginal wall, Apex and uterine prolapse. The support platform may be applicable in other pelvic organ disorder conditions, such as rectocele and urinary incontinence, as well as other clinical areas. In all these areas, there is an acute need for therapeutic solutions that deliver exceptional safety and long-term efficacy.

The company has a robust IP portfolio, including approved US and EU patents and pending applications in other regions.

The company is privately held and maintains research and development facilities and headquarters in Binyamina, Israel.

link to video